ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis

Oncogene

Volumn 33, Issue 17, 2014, Pages 2273-2278

  Okochi Takada, E ^a   Hattori, N ^a   Tsukamoto, T ^b   Miyamoto, K ^c   Ando, T ^a,d   Ito, S ^b   Yamamura, Y ^b   Wakabayashi, M ^a   Nobeyama, Y ^a,e   Ushijima, T ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c National Hospital Organization   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

angiogenesis; DNA methylation; epigenetics; gastric cancer; tumor suppressor

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE 4; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CPG ISLAND; DNA METHYLATION; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; STOMACH CANCER; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

AGED; AMINO ACID SEQUENCE; ANGIOPOIETINS; ANIMALS; BASE SEQUENCE; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84899620988     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.174     Document Type: Article

References (36)

1. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001; 1: 157-162.
2. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011; 11: 726-734.
3. Kishore R, Losordo DW. Gene therapy for restenosis: biological solution to a biological problem. J Mol Cell Cardiol 2007; 42: 461-468.
4. Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol 2010; 2: a001222.
5. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749-758.
6. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36: 417-422.
7. Shi Y, He B, You L, Jablons DM. Roles of secreted frizzled-related proteins in cancer. Acta Pharmacol Sin 2007; 28: 1499-1504.
8. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res 2002; 62: 6645-6650.
9. Hattori N, Okochi-Takada E, Kikuyama M, Wakabayashi M, Yamashita S, Ushijima T. Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas. Cancer Sci 2011; 102: 1337-1343.
10. Miida T, Hirayama S. Impacts of angiopoietin-like proteins on lipoprotein metabolism and cardiovascular events. Curr Opin Lipidol 2010; 21: 70-75.
11. Yang YH, Wang Y, Lam KS, Yau MH, Cheng KK, Zhang J et al. Suppression of the Raf/MEK/ERK signaling cascade and inhibition of angiogenesis by the carboxyl terminus of angiopoietin-like protein 4. Arterioscler Thromb Vasc Biol 2008; 28: 835-840.
12. Ito Y, Oike Y, Yasunaga K, Hamada K, Miyata K, Matsumoto S et al. Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4. Cancer Res 2003; 63: 6651-6657.
13. Chomel C, Cazes A, Faye C, Bignon M, Gomez E, Ardidie-Robouant C et al. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin- like 4 from proteolysis and regulates its antiangiogenic activity. FASEB J 2009; 23: 940-949.
14. Hermann LM, Pinkerton M, Jennings K, Yang L, Grom A, Sowders D et al. Angiopoietin-like-4 is a potential angiogenic mediator in arthritis. Clin Immunol 2005; 115: 93-101.
15. Ma T, Jham BC, Hu J, Friedman ER, Basile JR, Molinolo A et al. Viral G proteincoupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma. Proc Natl Acad Sci USA 2010; 107: 14363-14368.
16. Li KQ, Li WL, Peng SY, Shi XY, Tang HL, Liu YB. Anti-tumor effect of recombinant retroviral vector-mediated human ANGPTL4 gene transfection. Chin Med J (Engl) 2004; 117: 1364-1369.
17. Galaup A, Cazes A, Le Jan S, Philippe J, Connault E, Le Coz E et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA 2006; 103: 18721-18726.
18. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008; 133: 66-77.
19. Zhu P, Tan MJ, Huang RL, Tan CK, Chong HC, Pal M et al. Angiopoietin-like 4 protein elevates the prosurvival intracellular O2 - :H2O2 ratio and confers anoikis resistance to tumors. Cancer Cell 2011; 19: 401-415.
20. Nakayama T, Hirakawa H, Shibata K, Abe K, Nagayasu T, Taguchi T. Expression of angiopoietin-like 4 in human gastric cancer: ANGPTL4 promotes venous invasion. Oncol Rep 2010; 24: 599-606.
21. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988-993.
22. Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol 2007; 40: 142-150.
23. Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med 2008; 18: 6-14.
24. Oike Y, Akao M, Kubota Y, Suda T. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends Mol Med 2005; 11: 473-479.
25. Ge H, Yang G, Huang L, Motola DL, Pourbahrami T, Li C. Oligomerization and regulated proteolytic processing of angiopoietin-like protein 4. J Biol Chem 2004; 279: 2038-2045.
26. Yin W, Romeo S, Chang S, Grishin NV, Hobbs HH, Cohen JC. Genetic variation in ANGPTL4 provides insights into protein processing and function. J Biol Chem 2009; 284: 13213-13222.
27. Mei R, Galipeau PC, Prass C, Berno A, Ghandour G, Patil N et al. Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. Genome Res 2000; 10: 1126-1137.
28. Hoglund M, Gorunova L, Andren-Sandberg A, Dawiskiba S, Mitelman F, Johansson B. Cytogenetic and fluorescence in situ hybridization analyses of chromosome 19 aberrations in pancreatic carcinomas: frequent loss of 19p13.3 and gain of 19q13.1-13.2. Genes Chromosomes Cancer 1998; 21: 8-16.
29. Trojan J, Brieger A, Raedle J, Esteller M, Zeuzem S. 50-CpG island methylation of the LKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer. Gut 2000; 47: 272-276.
30. Sobottka SB, Haase M, Fitze G, Hahn M, Schackert HK, Schackert G. Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain. J Neurooncol 2000; 49: 187-195.
31. Tanner JE, Forte A, Panchal C. Nucleosomes bind fibroblast growth factor-2 for increased angiogenesis in vitro and in vivo. Mol Cancer Res 2004; 2: 281-288.
32. Zhu H, Zhang L, Wu S, Teraishi F, Davis JJ, Jacob D et al. Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3- dichlorophenoxy) propyl] amino]ethanol in correlation with activation of ERK. Oncogene 2004; 23: 4984-4992.
33. Asada K, Ando T, Niwa T, Nanjo S, Watanabe N, Okochi-Takada E et al. FHL1 on chromosome X is a single-hit gastrointestinal tumor-suppressor gene and contributes to the formation of an epigenetic field defect. Oncogene 2012; 32: 2140-2149.
34. Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer 2009; 124: 2367-2374.
35. Enomoto S, Maekita T, Tsukamoto T, Nakajima T, Nakazawa K, Tatematsu M et al. Lack of association between CpG island methylator phenotype in human gastric cancers and methylation in their background non-cancerous gastric mucosae. Cancer Sci 2007; 98: 1853-1861.
36. Ota N, Kawakami K, Okuda T, Takehara A, Hiranuma C, Oyama K et al. Prognostic significance of p16INK4a hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis. Anticancer Res 2006; 26: 3729-3732.